Citations

Clear

3138 citation(s) found for "Smith, AM".

Association of Premenopausal Bilateral Oophorectomy With Restless Legs Syndrome
Huo, Nan , Rocca, Liliana Gazzuola , Rocca, Walter A. , Gazzuola Rocca, Liliana, Smith, Carin Y. , Mielke, Michelle M. , Huo, Nan

Mayo Clinic

JAMA Network Open | February 2, 2021 | Volume: 4 | Issue: 2 | Pages: e2036058

10.1001/jamanetworkopen.2020.36058 | PMID 33523190 Get It

Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey
Akgül, Mahmut , Ertoy, Dilek, Argani, Pedram , Gupta, Sounak , Reuter, Victor E. , Tickoo, Satish K. , Netto, George J. , Hes, Ondřej , Hirsch, Michelle S. , Delahunt, Brett , Mehra, Rohit , Skala, Stephanie L. , Osunkoya, Adeboye O. , Harik, Lara R. , Nourieh, Maya , Zynger, Debra L. , Smith, Steven Cristopher, Nazeer, Tipu, Kulaç, İbrahim , Khani, Francesca , Tretiakova, Maria , Vakar‐Lopez, Funda , Barkan, Güliz A. , Molinié, Vincent , Verkarre, Virginie , Rao, Qiu , Kis, Lóránd, Panizo, Ángel , Farzaneh, Ted , Magers, Martin J. , Sanfrancesco, Joseph, Perrino, Carmen M. , Gondim, Dibson , Araneta, Ronald, So, Jeffrey , Ro, Jae Y. , Wasco, Matthew J., Hameed, Omar , Wobker, Sara E. , Melamed, Jonathan , Cheng, Liang , Idrees, Muhammad T. , Gumuskaya, Berrak , Samaratunga, Hemamali , Cheng, Liang , Skala, Stephanie L , Tretiakova, Maria S , Williamson, Sean R. , Caliò, Anna , Al-Ahmadie, Hikmat A , Rao, Priya , Sangoi, Ankur R. , López-Beltrán, Antonio , Samaratunga, Hemamali

Mayo Clinic

Journal of Clinical Pathology | January 29, 2021 | Volume: 74 | Issue: 5 | Pages: 291-299

10.1136/jclinpath-2020-207372 | PMID 33514585 Get It

Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features. 131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up. Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells with abundant cytoplasm were the most encountered cytologic feature, with either clear (almost always 10/50, 20%; frequently 34/50, 68%) or eosinophilic (almost always 4/49, 8%; frequently 28/49, 57%) cytology. Strong (3+) or diffuse (>75% of tumour cells) nuclear TFE3 IHC expression was considered diagnostic by 13/46 (28%) and 12/47 (26%) participants, respectively. Main TFE3 IHC issues were the low specificity (16/42, 38%), unreliable staining performance (15/42, 36%) and background staining (12/42, 29%). Most preferred IHC assays other than TFE3, cathepsin K and pancytokeratin were melan A (44/50, 88%), HMB45 (43/50, 86%), carbonic anhydrase IX (41/50, 82%) and CK7 (32/50, 64%). Cut-off for positive TFE3 fluorescent in situ hybridisation (FISH) was preferably 10% (9/50, 18%), although significant variation in cut-off values was present. 23/48 (48%) participants required TFE3 FISH testing to confirm TFE3-RCC regardless of the histomorphologic and IHC assessment. 28/50 (56%) participants would request additional molecular studies other than FISH assay in selected cases, whereas 3/50 participants use additional molecular cases in all cases when TFE3-RCC is in the differential. Optimal diagnostic approach on TFE3-RCC is impacted by IHC and/or FISH assay preferences as well as their conflicting interpretation methods.
Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib
Smith, Shane , Clark, Melanie A., Harker-Murray, Amy, Sokumbi, Olayemi , Sokumbi, Olayemi , Clarke, Callisia N.

Mayo Clinic

The American Journal of Dermatopathology | January 27, 2021 | Volume: 43 | Issue: 8 | Pages: 585-587

10.1097/dad.0000000000001849 | PMID 33534208 Get It

Abstract: Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.
Effect of Partial Uncinectomy After Balloon Sinuplasty on Maxillary Sinus Irrigant Penetration: A Cadaveric Study
Karataylι-Özgürsoy, Selmin, Gonzalez, Valeria , Olomu, Osarenoma , Donaldson, Angela M. , Martinez-Paredes, Jhon F, Karatayli-Ozgursoy, Selmin, Gonzalez, Valeria V , Martinez‐Paredes, Jhon F.

Mayo Clinic

OTO Open | January 27, 2021 | Volume: 5 | Issue: 1 | Pages: No page available

10.1177/2473974x21989583 | PMID 33598598 Get It

ObjectiveThe uncinate process may play a role in the amount of irrigation penetrance. In this cadaver study, we aimed to investigate if the addition of partial uncinectomy provides better maxillary sinus irrigation penetrance than balloon sinuplasty (BSP) alone.Study DesignCadaveric study.SettingSimulation laboratory at the Mayo Clinic in Florida.MethodsFive fresh‐frozen human cadaveric heads (10 sides) were used to assess maxillary sinus irrigation penetration after 3 interventions performed sequentially: irrigation penetrance with no intervention, irrigation after BSP, and irrigation after BSP and partial removal of the uncinate. Penetrance was recorded with intrasinus endoscopy and scored by 4 blinded observers using a scale from 0 (no irrigation) to 5 (fully irrigated). The diameter of the maxillary ostium was measured before and after BSP. Internal consistency was evaluated with Cronbach’s alpha.ResultsMean ostium size increased from 4.1 to 6.8 mm after BSP (P =. 013). Cronbach’s alpha was 0.93. The median scores of irrigation penetration after no intervention, BSP, and BSP and partial uncinectomy were 2.5, 3, and 4, respectively. We found a significantly higher penetrance following partial uncinectomy plus BSP versus BSP alone (P =. 008). Both interventions had a statistically significant difference in irrigation penetrance as compared with no intervention (P =. 0001).ConclusionMaxillary sinus irrigation penetration increased from baseline after BSP. The addition of a partial uncinectomy to the balloon dilation of the maxillary sinus was associated with a statistically significant increase in irrigation penetrance scores as compared with BSP alone.
Content and Accessibility of United States Medical School Websites During COVID-19 and the Online Interview Season
Moore, Marlena, Smith, Jacob , Woolstenhulme, Jonathan B. , Markham, Dane J. , Rhees, Joshua, Poole, Kenneth , Patel, Naresh K. , Pollock, Jordan Riley , Patel, Naresh

Mayo Clinic

No container title available | January 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-147236/v1 Get It

Abstract BackgroundMost medical school applicants use the internet as a source of information when applying for medical school. Previous analyses have evaluated residency and fellowship websites, however, an in-depth analysis regarding medical school websites is lacking.MethodsWe evaluated 192 United States medical school websites for presence or absence of 39 items relevant to medical school applicants. Items fell into 7 general categories: curriculum, research, demographics of incoming class, admissions information, faculty, financial aid, and social.ResultsOf the 192 websites evaluated (152 allopathic and 40 osteopathic schools), websites contained a mean of 23 items (59%) with a standard deviation of 4.2 items. ConclusionOur study examining United States Medical School websites revealed a lack of online information for medical school applicants. As medical school interviews transition to being online during the COVID-19 pandemic, the importance of the medical school website to applicants becomes increasingly crucial. The information contained in our study could be used to improve accessibility and information on medical school websites, which could help both applicants and medical schools themselves.
Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.
Smith, Caleb J. , Cook, Kathryn , Hanna, Mina, Jin, Zhaohui , Jochum, Jacob A., Mitchell, Jessica L. , Pitot, Henry C., Jatoi, Aminah , Jin, Zhaohui , Bekaii‐Saab, Tanios , Eiring, Rachel A. , Hálfdánarson, Þorvarður R. , Wee, Wen

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 402-402

10.1200/jco.2021.39.3_suppl.402 Get It

402 Background: Pancreas cancer is an aggressive malignancy with limited therapeutic options. Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment, and current guidelines recommend its use in the absence of prior irinotecan. This study aimed to assess whether patients who had received regular irinotecan derive benefit from Nal-IRI. Methods: Medical records of metastatic pancreas cancer patients who had received regular irinotecan and then Nal-IRI were reviewed. The following information was extracted from each medical record: patient demographics, confirmation of a diagnosis of exocrine pancreas cancer, initial cancer stage, dates of administration of the drugs of interest, adverse events that occurred with Nal-IRI treatment, reasons for stopping regular irinotecan, and reasons for starting and stopping Nal-IRI. The primary endpoint was overall survival after the initiation of Nal-IRI (an a priori threshold of > 4 months defined success). Survival data were censored based on date of last follow up. Direct quotes from the medical record were documented to provide insight on prescribing Nal-IRI when guidelines advised the contrary. Results: Sixty four patients met eligibility criteria with a median age of 65 years (range: 36, 80 years). Prior to Nal-IRI, 61 patients had received FOLFIRINOX, and 3 FOLFIRI. Of these, 32 patients manifested progressive disease on regular irinotecan-based therapy. Nal-IRI was prescribed with a fluoropyrimidine; only one patient received monotherapy. At time of analysis, 54 patients had died. Median overall survival from initiation of Nal-IRI was 5.1 months (95% confidence interval (CI): 5.6, 4.3, months). An exploratory comparison, based on no cancer progression with regular irinotecan versus progression, showed improved survival with Nal-IRI in the former group: 6.1 months (95% CI: 9.3, 5.1 months) versus 4.3 months (95% CI: 4.8, 2.3 months); p=0.0006. Nal-IRI adverse events occurred as expected. Qualitative data illustrated several themes, including “limited treatment options,” which appeared to drive the decision to prescribe Nal-IRI. Conclusions: Nal-IRI might be considered in pancreas cancer patients who had received regular irinotecan, particularly in the absence of disease progression with the latter.
Commentary: A Novel Method to Treat Progressive Desmoid Tumors Involving Neurovascular Bundles: A Retrospective Cohort Study
Jack, Megan M. , Smith, Brandon W. , Spinner, Robert J.

Mayo Clinic

Neurosurgery | January 21, 2021 | Volume: 88 | Issue: 6 | Pages: E489-E490

10.1093/neuros/nyab026 | PMID 33582819 Get It

Intraoperative prothrombin complex concentrate administration and outcomes in patients undergoing left ventricular assist device implantation
Boswell, Michael R. , Stulak, John M., Weber, Matthew P. , Tchantchaleishvili, Vakhtang , Weber, Matthew P , Smith, Mark M , Boswell, Michael R., Tchantchaleishvili, Vakhtang , Warner, Matthew A. , Smith, Bradford B. , Smith, Mark M.

Mayo Clinic

Artificial Organs | January 20, 2021 | Volume: 45 | Issue: 8 | Pages: No page available

10.1111/aor.13918 | PMID 33469913 Get It

Abstract Prothrombin complex concentrate (PCC) administration has increased among cardiac surgery patients in recent years; however, use in LVAD implantation/exchange is not widespread due to the fear of thrombotic complications. The purpose of this study was to compare the clinical outcomes of patients undergoing LVAD implantation/exchange with intraoperative PCC administration versus traditional transfusion practices alone. Adult LVAD implants/exchanges at our institution between 2015 and 2018 were included. Patients were categorized as receiving intraoperative PCC or no‐PCC (traditional). The primary outcome was the need for allogenic transfusion and transfusion volume at 48 hours after initial intensive care unit (ICU) admission. Secondary outcomes included metrics of morbidity and mortality. A total of 160 patients (39 PCC, 121 traditional) were analyzed. In unadjusted analysis, patients in the PCC group received lower intraoperative transfusion volumes compared to the traditional group although not statistically significant (1464 mL [IQR 796, 4876] vs. 2568 mL [IQR 1292, 3606]; P value .37). In the fully adjusted analysis, patients in the PCC group had increased odds of transfusion within 48 hours of ICU admission (OR 4.06, 95% CI: 1.35‐12.20; P < .01); however, there was no significant difference in transfusion volumes ( P = .09). Patients receiving PCCs had higher incidence of deep vein thrombosis (10.3% vs. 0%; P < .01) and 30‐day mortality (17.9% vs. 4.1%; P < .01). LVAD pump thrombosis occurred in 2.6% versus 0.8% in the PCC and traditional groups, respectively; P = .98. Patients undergoing LVAD implantation and exchange represent a complex surgical cohort. The results of this study suggest that the intraoperative PCC use during LVAD implant/exchange was associated with reduced intraoperative transfusions. Intraoperative PCC use was, however, associated with higher odds of postoperative transfusion, although transfusion volumes were not significantly different. While the deep vein thrombosis and 30‐day mortality rates were higher in the PCC group, these results are likely related to the degree of surgical and patient complexity rather than PCC use itself. Further studies are needed to assess PCC use in this surgical cohort.